{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:05:07Z","timestamp":1778724307570,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We explored antibody response after first and second BNT162b2 vaccinations, to predict the need for subsequent injections in nursing home (NH) residents. 369 NH residents were tested for IgG against SARS-CoV-2 Receptor-Binding Domain (RBD-IgG) and nucleoprotein-IgG (SARS-CoV-2 IgG II Quant and SARS-CoV-2 IgG Alinity assays, Abbott Diagnostics). In NH residents with prior SARS-CoV-2 infection, the first dose elicited high RBD-IgG levels (\u2265\u20094160\u00a0AU\/mL) in 99\/129 cases (76.9%), with no additional antibody gain after the second dose in 74 cases (74.7%). However, a low RBD-IgG level (&lt;\u20091050\u00a0AU\/mL) was observed in 28 (21.7%) residents. The persistence of nucleoprotein-IgG and a longer interval between infection and the first dose were associated with a higher RBD-IgG response (p\u2009&lt;\u20090.0001 and p\u2009=\u20090.0013, respectively). RBD-IgG below 50\u00a0AU\/mL after the first dose predicted failure to reach the antibody concentration associated with a neutralizing effect after the second dose (\u2265\u20091050\u00a0AU\/mL). The BNT162b2 vaccine elicited a strong humoral response after the first dose in a majority of NH residents with prior SARS-CoV-2 infection. However, about one quarter of these residents require a second injection. Consideration should be given to immunological monitoring in NH residents to optimize the vaccine response in this vulnerable population.<\/jats:p>","DOI":"10.1038\/s41598-022-18041-x","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:05:18Z","timestamp":1660313118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents"],"prefix":"10.1038","volume":"12","author":[{"given":"Edouard","family":"Tuaillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Pisoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Veyrenche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Rafasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Niel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Gros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Muriaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Picot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Aouinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Van de Perre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Blain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"18041_CR1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/ageing\/afab098","volume":"50","author":"F Canou\u00ef-Poitrine","year":"2021","unstructured":"Canou\u00ef-Poitrine, F. et al. Magnitude, change over time, demographic characteristics and geographic distribution of excess deaths among nursing home residents during the first wave of COVID-19 in France: A nationwide cohort study. Age Ageing 50, 1473\u20131481 (2021).","journal-title":"Age Ageing"},{"key":"18041_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/cid\/ciab446","volume":"74","author":"B Bailly","year":"2022","unstructured":"Bailly, B. et al. BNT162b2 messenger RNA vaccination did not prevent an outbreak of severe acute respiratory syndrome coronavirus 2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity. Clin. Infect. Dis. 74, 517\u2013520. https:\/\/doi.org\/10.1093\/cid\/ciab446 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"18041_CR3","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1111\/all.15142","volume":"77","author":"H Blain","year":"2022","unstructured":"Blain, H. et al. Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks. Allergy 77, 1885\u20131894. https:\/\/doi.org\/10.1111\/all.15142 (2022).","journal-title":"Allergy"},{"key":"18041_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.15585\/mmwr.mm7034e3","volume":"70","author":"S Nanduri","year":"2021","unstructured":"Nanduri, S. et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant\u2014National Healthcare Safety Network, March 1\u2013August 1, 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 1163\u20131166 (2021).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"18041_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417\u2013422 (2021).","journal-title":"Nature"},{"key":"18041_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamda.2021.12.001","volume":"23","author":"AH Dyer","year":"2022","unstructured":"Dyer, A. H. et al. Previous SARS-CoV-2 infection, age, and frailty are associated with 6-month vaccine-induced anti-spike antibody titer in nursing home residents. J. Am. Med. Dir. Assoc. 23, 434\u2013439 (2022).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"18041_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103805","volume":"75","author":"G Moncunill","year":"2022","unstructured":"Moncunill, G. et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and na\u00efve healthcare workers. EBioMedicine 75, 103805 (2022).","journal-title":"EBioMedicine"},{"key":"18041_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab963","author":"DH Canaday","year":"2021","unstructured":"Canaday, D. H. et al. Significant reduction in vaccine-induced antibody levels and neutralization activity among healthcare workers and nursing home residents 6\u00a0months following coronavirus disease 2019 BNT162b2 mRNA vaccination. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab963 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"18041_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","volume":"27","author":"JE Ebinger","year":"2021","unstructured":"Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981\u2013984 (2021).","journal-title":"Nat. Med."},{"key":"18041_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1001\/jama.2021.3341","volume":"325","author":"S Saadat","year":"2021","unstructured":"Saadat, S. et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA 325, 1467 (2021).","journal-title":"JAMA"},{"key":"18041_CR11","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1001\/jama.2021.6042","volume":"325","author":"H Blain","year":"2021","unstructured":"Blain, H. et al. Spike antibody levels of nursing home residents with or without prior COVID-19 3\u00a0weeks after a single BNT162b2 vaccine dose. JAMA 325, 1898 (2021).","journal-title":"JAMA"},{"key":"18041_CR12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3201\/eid2708.210887","volume":"27","author":"P Tober-Lau","year":"2021","unstructured":"Tober-Lau, P. et al. Outbreak of SARS-CoV-2 B.1.1.7 lineage after vaccination in long-term care facility, Germany, February\u2013March 2021. Emerg. Infect. Dis. 27, 2169\u20132173 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"18041_CR13","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"18041_CR14","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"18041_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430\u2013436 (2020).","journal-title":"Nature"},{"key":"18041_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"40","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini, A. et al. Vaccination in the elderly: The challenge of immune changes with aging. Semin. Immunol. 40, 83\u201394 (2018).","journal-title":"Semin. Immunol."},{"key":"18041_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jamda.2020.06.013","volume":"21","author":"H Blain","year":"2020","unstructured":"Blain, H. et al. Efficacy of a test-retest strategy in residents and health care personnel of a nursing home facing a COVID-19 outbreak. J. Am. Med. Dir. Assoc. 21, 933\u2013936 (2020).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"18041_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/ageing\/afab050","volume":"50","author":"H Blain","year":"2021","unstructured":"Blain, H. et al. Atypical symptoms, SARS-CoV-2 test results and immunisation rates in 456 residents from eight nursing homes facing a COVID-19 outbreak. Age Ageing 50, 641\u2013648 (2021).","journal-title":"Age Ageing"},{"key":"18041_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s41999-020-00352-9","volume":"11","author":"H Blain","year":"2020","unstructured":"Blain, H. et al. Atypical clinical presentation of COVID-19 infection in residents of a long-term care facility. Eur. Geriatr. Med. 11, 1085\u20131088 (2020).","journal-title":"Eur. Geriatr. Med."},{"key":"18041_CR20","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1056\/NEJMc2103916","volume":"384","author":"N Doria-Rose","year":"2021","unstructured":"Doria-Rose, N. et al. Antibody persistence through 6\u00a0months after the second dose of mRNA-1273 vaccine for Covid-19. N. Engl. J. Med. 384, 2259\u20132261 (2021).","journal-title":"N. Engl. J. Med."},{"key":"18041_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00288-21","volume":"59","author":"E English","year":"2021","unstructured":"English, E. et al. Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods. J. Clin. Microbiol. 59, e0028821 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"18041_CR22","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/cid\/ciab300","volume":"73","author":"JT Van Praet","year":"2021","unstructured":"Van Praet, J. T., Vandecasteele, S., De Roo, A., De Vriese, A. S. & Reynders, M. Humoral and cellular immunogenicity of the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in nursing home residents. Clin. Infect. Dis. 73, 2145\u20132147. https:\/\/doi.org\/10.1093\/cid\/ciab300 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"18041_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"18041_CR24","doi-asserted-by":"publisher","first-page":"1516.e7","DOI":"10.1016\/j.cmi.2021.05.041","volume":"27","author":"DW Eyre","year":"2021","unstructured":"Eyre, D. W. et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer\u2013BioNTech and Oxford\u2013AstraZeneca vaccines by previous infection status. Clin. Microbiol. Infect. 27, 1516.e7-1516.e14 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"18041_CR25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2021.2352","volume":"325","author":"R Gharpure","year":"2021","unstructured":"Gharpure, R., Patel, A. & Link-Gelles, R. First-dose COVID-19 vaccination coverage among skilled nursing facility residents and staff. JAMA 325, 1670 (2021).","journal-title":"JAMA"},{"key":"18041_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149150","volume":"131","author":"A Mazzoni","year":"2021","unstructured":"Mazzoni, A. et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J. Clin. Investig. 131, e149150 (2021).","journal-title":"J. Clin. Investig."},{"key":"18041_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103589","volume":"72","author":"B Appelman","year":"2021","unstructured":"Appelman, B. et al. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. EBioMedicine 72, 103589 (2021).","journal-title":"EBioMedicine"},{"key":"18041_CR28","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1016\/S0264-410X(01)00246-8","volume":"19","author":"EM Gardner","year":"2001","unstructured":"Gardner, E. M. et al. Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population. Vaccine 19, 4610\u20134617 (2001).","journal-title":"Vaccine"},{"key":"18041_CR29","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S2666-7568(21)00168-9","volume":"2","author":"G Tut","year":"2021","unstructured":"Tut, G. et al. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): An observational study. Lancet Healthy Longev. 2, e544\u2013e553 (2021).","journal-title":"Lancet Healthy Longev."},{"key":"18041_CR30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","volume":"70","author":"WH Self","year":"2021","unstructured":"Self, W. H. et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2014United States, March\u2013August 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 1337\u20131343 (2021).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"18041_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2021.1974540","author":"H Soeorg","year":"2021","unstructured":"Soeorg, H. et al. Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination. Infect. Dis. https:\/\/doi.org\/10.1080\/23744235.2021.1974540 (2021).","journal-title":"Infect. Dis."},{"key":"18041_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96171-4","volume":"11","author":"W Xia","year":"2021","unstructured":"Xia, W. et al. Longitudinal analysis of antibody decay in convalescent COVID-19 patients. Sci. Rep. 11, 16796 (2021).","journal-title":"Sci. Rep."},{"key":"18041_CR33","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 385, 1393\u20131400 (2021).","journal-title":"N. Engl. J. Med."},{"key":"18041_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01540-1 (2021).","journal-title":"Nat. Med."},{"key":"18041_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/jmv.27485","volume":"94","author":"S Falahi","year":"2022","unstructured":"Falahi, S. & Kenarkoohi, A. Host factors and vaccine efficacy: Implications for COVID-19 vaccines. J. Med. Virol. 94, 1330\u20131335 (2022).","journal-title":"J. Med. Virol."},{"key":"18041_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"Q-X Long","year":"2020","unstructured":"Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"18041_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","volume":"21","author":"D Cromer","year":"2021","unstructured":"Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21, 395\u2013404 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"18041_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01729-z","author":"R Stellini","year":"2021","unstructured":"Stellini, R. et al. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection. Infection https:\/\/doi.org\/10.1007\/s15010-021-01729-z (2021).","journal-title":"Infection"},{"key":"18041_CR39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jinf.2021.10.011","volume":"84","author":"Y Chong","year":"2022","unstructured":"Chong, Y. et al. Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents. J. Infect. 84, 418\u2013467 (2022).","journal-title":"J. Infect."},{"key":"18041_CR40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri2508","volume":"9","author":"C-A Siegrist","year":"2009","unstructured":"Siegrist, C.-A. & Aspinall, R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9, 185\u2013194 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"18041_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8\u00a0months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"18041_CR42","unstructured":"National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Interim Guidelines for COVID-19 Antibody Testing Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings (2022)."},{"key":"18041_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s41999-020-00405-z","volume":"11","author":"H Blain","year":"2020","unstructured":"Blain, H. et al. August 2020 Interim EuGMS guidance to prepare European long-term care facilities for COVID-19. Eur. Geriatr. Med. 11, 899\u2013913 (2020).","journal-title":"Eur. Geriatr. Med."},{"key":"18041_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6950","volume":"6","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination. Sci. Immunol. 6, eabi6950 (2021).","journal-title":"Sci. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18041-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18041-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18041-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:23:39Z","timestamp":1669361019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18041-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18041"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18041-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"9 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13749"}}